Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma

specific

A T-cell/histiocyte-rich large B-cell lymphoma that is resistant to treatment.

23

Centers

30

Active Trials

Cancer Funding

Top Centers for Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma(23)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
Active Research Program
67.8
2
NCI Comprehensive
Active Research Program
67.8
367.8
4
NCI Comprehensive
Active Research Program
67.8
5
Active Research Program
67.8
6
Active Research Program
67.8
7
Active Research Program
67.8
8
NCI Comprehensive
Active Research Program
45.3
9
NCI Comprehensive
Active Research Program
45.3
10
NCI Comprehensive
Active Research Program
45.3
11
NCI Comprehensive
Active Research Program
45.3
12
NCI Comprehensive
Active Research Program
45.3
13
NCI Comprehensive
Active Research Program
45.3
14
NCI Comprehensive
Active Research Program
45.3
15
Active Research Program
45.3
16
Cedars-Sinai CancerLos Angeles, CA
Active Research Program
45.3
17
NCI Comprehensive
Active Research Program
45.3
18
NCI Clinical
Active Research Program
45.3
19
NCI Comprehensive
Active Research Program
45.3
20
NCI Comprehensive
Active Research Program
45.3
21
Active Research Program
45.3
22
Active Research Program
45.3
23
Active Research Program
45.3

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →